(Q43638445)

25 November 2017

title

Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients (English)

1 reference

25 November 2017

0 references

1 reference

E Esel

1

1 reference

25 November 2017

M Basturk

2

1 reference

25 November 2017

A Saffet Gonul

3

1 reference

25 November 2017

M Kula

4

1 reference

25 November 2017

M Tayfun Turan

5

1 reference

25 November 2017

I Yabanoglu

6

1 reference

25 November 2017

S Sofuoglu

7

1 reference

25 November 2017

publication date

1 August 2001

1 reference

25 November 2017

published in

Psychoneuroendocrinology

1 reference

25 November 2017

volume

26

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

641-647

1 reference

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900016-6

7 January 2021

10.1016/S0306-4530(01)00016-6

Identifiers

DOI

1 reference

25 November 2017

1 reference